Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antisense oligonucleotides targeting PVT1
- Development stage
- Preclinical
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Antisense oligonucleotides (ASOs) targeting the long non-coding RNA (lncRNA) PVT1 are experimental therapeutic agents designed to silence the PVT1 oncogene. PVT1 is frequently overexpressed in various cancers, including gastric adenocarcinoma, esophageal adenocarcinoma, and acute myeloid leukemia (AML). These ASOs, which include LNA GapmeR variants, function by binding to PVT1 transcripts (both linear and circular isoforms) and inducing RNase H-dependent degradation. Preclinical research, notably involving Ionis Pharmaceuticals and MD Anderson Cancer Center, has shown that PVT1 silencing can inhibit leukemia cell growth, induce apoptosis, and sensitize tumor cells to DNA damage response (DDR) inhibitors like ATM or ATR inhibitors.
- Other names
- PVT1 ASOsPVT-1 ASOsPVT 1 ASOsantisense LNA GapmeR variants targeting PVT1
02
Targets
PVT1 (Plasmacytoma variant translocation 1)
Beyond the preview
Go deeper on antisense oligonucleotides targeting PVT1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antisense oligonucleotides targeting PVT1.